Clinical Scorecard: Assessing Infection Risk in Patients with Inflammatory Bowel Disease Undergoing Vedolizumab Treatment: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Vedolizumab (VDZ) targets α4β7 integrin, inhibiting lymphocyte trafficking to the intestinal mucosa. [Source needed]
Target Population
Care Setting
Key Highlights
VDZ showed no significant difference in infection risk compared to TNF inhibitors or placebo. [Source needed]
Guideline-Based Recommendations
Diagnosis
Management
V
D
Z
c
a
n
b
e
u
s
e
d
a
s
m
o
n
o
t
h
e
r
a
p
y
o
r
i
n
c
o
m
b
i
n
a
t
i
o
n
w
i
t
h
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
.
[
S
o
u
r
c
e
n
e
e
d
e
d
]
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Real-world data indicate VDZ induces clinical remission in 40–60% of IBD patients. [Source needed]
Clinical Best Practices
Consider comparative risk assessment when choosing between VDZ and other therapies. [Source needed]
